Tags

Type your tag names separated by a space and hit enter

Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease.
Br J Haematol 2000; 111(2):498-500BJ

Abstract

To determine the effects of L-arginine (L-Arg) supplementation on nitric oxide metabolite (NOx) production, oral L-Arg was given to normal controls, sickle cell disease (SCD) patients at steady state and SCD patients hospitalized with a vaso-occlusive crisis (VOC). L-Arg (0.1 g/kg) increased NOx formation by 18.8 +/- 68% in normal controls, whereas steady-state SCD patients demonstrated a paradoxical decrease in NOx of -16.7 +/- 4% (P = 0.004). In contrast, patients with VOC demonstrated a dramatic increase in NOx production by +77.7 +/- 103%, a response that was dose dependent. L-Arg appears to be the rate-limiting step in NOx production during VOC. Oral arginine may therefore benefit SCD patients by inducing an increase in NO production during VOC.

Authors+Show Affiliations

Department of Emergency Medicine, Children's Hospital Oakland, CA 94609, USA. johnclaud@home.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11122090

Citation

Morris, C R., et al. "Arginine Therapy: a Novel Strategy to Induce Nitric Oxide Production in Sickle Cell Disease." British Journal of Haematology, vol. 111, no. 2, 2000, pp. 498-500.
Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol. 2000;111(2):498-500.
Morris, C. R., Kuypers, F. A., Larkin, S., Sweeters, N., Simon, J., Vichinsky, E. P., & Styles, L. A. (2000). Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. British Journal of Haematology, 111(2), pp. 498-500.
Morris CR, et al. Arginine Therapy: a Novel Strategy to Induce Nitric Oxide Production in Sickle Cell Disease. Br J Haematol. 2000;111(2):498-500. PubMed PMID: 11122090.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. AU - Morris,C R, AU - Kuypers,F A, AU - Larkin,S, AU - Sweeters,N, AU - Simon,J, AU - Vichinsky,E P, AU - Styles,L A, PY - 2000/12/21/pubmed PY - 2001/3/3/medline PY - 2000/12/21/entrez SP - 498 EP - 500 JF - British journal of haematology JO - Br. J. Haematol. VL - 111 IS - 2 N2 - To determine the effects of L-arginine (L-Arg) supplementation on nitric oxide metabolite (NOx) production, oral L-Arg was given to normal controls, sickle cell disease (SCD) patients at steady state and SCD patients hospitalized with a vaso-occlusive crisis (VOC). L-Arg (0.1 g/kg) increased NOx formation by 18.8 +/- 68% in normal controls, whereas steady-state SCD patients demonstrated a paradoxical decrease in NOx of -16.7 +/- 4% (P = 0.004). In contrast, patients with VOC demonstrated a dramatic increase in NOx production by +77.7 +/- 103%, a response that was dose dependent. L-Arg appears to be the rate-limiting step in NOx production during VOC. Oral arginine may therefore benefit SCD patients by inducing an increase in NO production during VOC. SN - 0007-1048 UR - https://www.unboundmedicine.com/medline/citation/11122090/Arginine_therapy:_a_novel_strategy_to_induce_nitric_oxide_production_in_sickle_cell_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0007-1048&date=2000&volume=111&issue=2&spage=498 DB - PRIME DP - Unbound Medicine ER -